Multiple Sclerosis (MS) Drug Market

NPR  Jul 14  Comment 
The innovative drug Ocrevus looks as if it could be a game-changer for people with MS. But it's very, very expensive. And as with any new medication, the long-term safety risks are unknown.
Mondo Visione  Jul 4  Comment 
The October Club, a committee of philanthropists based in the City, officially launched its partnership with its chosen annual charity, Multiple Sclerosis (MS) Trust, at the House of Commons yesterday. The event was hosted by Baroness Wheatcroft,...
FiercePharma  Jun 22  Comment 
The medical world has found no causal relationship between hepatitis B vaccine and nervous system diseases such as multiple sclerosis, but the Court of Justice of the European Union just rendered such scientific evidence unnecessary in confirming...
Motley Fool  Jun 8  Comment 
The threat of increasing competition for GW Pharmaceuticals' promising epilepsy drug took a toll on investors' confidence last month.
FierceBiotech  May 26  Comment 
Missing a secondary endpoint in the RADIANCE trial won't hinder the launch or commercial success of ozanimod, CFO Peter Kellogg tells Barclays analysts.
FiercePharma  May 24  Comment 
Roche’s new drug Ocrevus has landed in the same sentence with the three letters all makers of multiple sclerosis drugs dread: PML.
MarketWatch  May 22  Comment 
Celgene Corp. shares rose about 1% premarket before surrendering their gains, after the company reported positive results from a late-stage trial of a treatment for multiple sclerosis. Celgene said the phase III trial of ozanimod, an...
GenEng News  May 9  Comment 
Nashville-based specialty diagnostic technology company IQuity says it will begin taking orders from enrolled physicians for IsolateMS, reportedly the first RNA-based diagnostic test for multiple sclerosis (MS), in late May. The product...
FierceBiotech  May 8  Comment 
Teva, Active Biotech chalk up another phase 3 failure for once-hyped Copaxone heir laquinimod in multiple sclerosis nptaylor Mon, 05/08/2017 - 04:30


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki